Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight

globenewswire.com
CYTK Mentioned as a key company in the chronic heart failure market, indicating potential involvement in pipeline development and future growth opportunities. BAYRY LLY BCDA Named as a key company in the chronic heart failure market and also in the acute coronary syndrome market, indicating potential involvement in pipeline development. MESO Mentioned as a key company in the chronic heart failure market, suggesting potential contributions to pipeline development and future growth. TNSA NVO Appears in both the chronic heart failure and acute coronary syndrome markets, suggesting potential pipeline contributions and involvement in related therapeutic areas. AZN Mentioned in both chronic heart failure and acute coronary syndrome markets, indicating potential contributions to pipeline development in these cardiovascular areas. BMY ITCI JNJ AMGN Mentioned as a key company in the acute coronary syndrome market, indicating potential contributions to pipeline development and future growth. ARWR Listed as a key company in the acute coronary syndrome market, suggesting potential involvement in pipeline development and future growth opportunities.

New York, USA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight

Chronic heart failure (CHF) is a progressive condition where the heart is unable to pump blood effectively, leading to significant morbidity and healthcare burden. The growing elderly population, inherently at higher risk for CHF, is a major driver of market expansion. The rising prevalence of comorbidities like obesity, diabetes, and hypertension is accelerating disease incidence and increasing demand for advanced therapies.

DelveInsight’s ' Chronic Heart Failure Pipeline Insight 2025' report provides comprehensive global coverage of pipeline therapies for chronic heart failure across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the chronic heart failure domain.

Chronic Heart Failure Clinical Trial Analysis Summary

Request a sample and discover the recent advances in chronic heart failure drugs @ Chronic Heart Failure Pipeline Report

What is Chronic Heart Failure?

Chronic heart failure is a significant public health concern in developed countries, with its incidence reaching nearly 10 cases per 1,000 people over the age of 65. The prevalence of CHF is strongly age-related, affecting less than 1% of individuals between 45 and 55 years, 2–5% in those aged 65–75 years, and approximately 10% in people aged 80 years or older. Heart failure is a complex clinical syndrome marked by the heart’s inability to pump sufficient blood to meet the body’s needs at normal filling pressures. This ventricular dysfunction reduces exercise capacity and often diminishes quality of life. From a clinical perspective, forward failure of the heart manifests as low blood pressure and fatigue, whereas backward failure results in shortness of breath and fluid accumulation, leading to pulmonary congestion, pleural effusions, peripheral edema, and dysfunction of organs such as the liver, stomach, and kidneys. Common complications include arrhythmias, thromboembolic events, pulmonary edema, cardiogenic shock, and ultimately death.

Find out more about chronic heart failure drugs @ Chronic Heart Failure Treatment

A snapshot of the Pipeline Chronic Heart Failure Drugs mentioned in the report:

Learn more about the emerging chronic heart failure therapies @ Chronic Heart Failure Clinical Trials

Recent Developments in Chronic Heart Failure Treatment Space

Scope of the Chronic Heart Failure Pipeline Report

Dive deep into rich insights for new chronic heart failure treatments, visit @ Chronic Heart Failure Drugs

Table of Contents

For further information on the chronic heart failure pipeline therapeutics, reach out @ Chronic Heart Failure Therapeutics

Related Reports

Chronic Heart Failure Epidemiology Forecast

Chronic Heart Failure Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted CHF epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Heart Failure Market

Chronic Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Chronic Heart Failure companies, including Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, among others.

Acute Coronary Syndrome Market

Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ACS companies, including Novartis, Boehringer Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, among others.

Acute Coronary Syndrome Clinical Trial Analysis

Acute Coronary Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute coronary syndrome companies, including Janssen Research & Development, LLC, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Connect with us at LinkedIn